Street Calls of the Week
Investing.com - Theravance Biopharma (NASDAQ:TBPH) received a reiterated Buy rating from BTIG, which maintained its $25.00 price target on the stock. The target represents significant upside potential from the current price of $13.80, with analyst targets ranging from $13 to $26. According to InvestingPro data, the stock has shown remarkable momentum with a 69.47% return over the past year and is currently trading near its 52-week high of $14.30. The reaffirmation comes as the company completed enrollment in the open-label portion of its Phase 3 CYPRESS trial for symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA). With a market capitalization of $701.53 million and a "GREAT" financial health score from InvestingPro, Theravance appears well-positioned to advance its clinical programs. Investors seeking deeper insights can access comprehensive analysis through InvestingPro’s detailed research reports, available for over 1,400 US stocks including TBPH.
Data from the CYPRESS trial remains on track for release in the first quarter of 2026, approximately six months following the completion of enrollment. BTIG views the CYPRESS trial as significantly derisked by preceding Phase 3 results from Study 0170, where ampreloxetine showed positive trends on OHSA composite score and individual symptom scales without worsening supine hypertension.
The absence of supine hypertension risk with ampreloxetine could emerge as an important differentiator, as both currently approved treatment options for nOH carry boxed warnings for this side effect. Dr. Horacio Kaufmann, Professor of Neurology and Professor of Medicine at NYU Grossman School of Medicine, has indicated intent to prescribe ampreloxetine to "the majority" of his patients with nOH due to MSA if CYPRESS confirms the benefits seen in Study 0170.
CYPRESS was designed in collaboration with the FDA and incorporates a shorter open-label period and longer randomized withdrawal period compared to Study 0170, which could increase the probability of demonstrating a more pronounced effect. The trial utilizes the OHSA composite score instead of only the OHSA #1 score to account for benefits across various symptoms and minimize variability due to individual patient differences.
Theravance Biopharma utilized an external enrollment committee comprised of the same clinical neurologists for both Study 0170 and CYPRESS to ensure consistency in enrollment and enrichment criteria, supporting potential positive readthrough between the two trials. The company maintains strong financial flexibility with a current ratio of 6.7 and holds more cash than debt on its balance sheet, providing stability as it advances through clinical development.
In other recent news, Theravance Biopharma reported impressive financial results for the second quarter of 2025, exceeding analyst expectations. The company achieved earnings per share of $1.08, surpassing the projected $0.67, and reported revenue of $26.2 million, which was significantly higher than the estimated $15.92 million. These results represent a 61.19% surprise in earnings per share and a 64.57% surprise in revenue. Additionally, Theravance reached a settlement with Cipla Limited and Cipla USA, Inc. regarding patent litigation over YUPELRI inhalation solution. The settlement also involved Mylan Ireland Limited and Viatris Specialty L.P. and resolves litigation under the Hatch-Waxman Act. Furthermore, Leerink Partners raised its price target for Theravance Biopharma to $13.00 from $10.00, maintaining a Market Perform rating. This adjustment follows Theravance’s completion of its Trelegy royalty sale for $225 million and a $7.5 million milestone payment for Yupelri’s approval in China. These developments highlight Theravance’s recent progress and achievements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.